Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics Inc.

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Arcutis Biotherapeutics today and set a price target of $26.00. The company’s shares op...

Current Quarter	$0.02	Next Quarter	$-0.02
Current Year	$-0.24	Next Year	$0.41
QoQ Growth	-200.0%	YoY Growth	+270.8%
3Y EPS CAGR	+34.8%	Target Price	$30.38
Consensus	Buy	Upside	+3.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARQT	$29.49	+7.90%	2.59M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARQT	$29.49	+7.9%	2.59M
3
4
5
6

ARQT

ARQT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Arcutis Biotherapeutics Inc. Data in Excel

Get Arcutis Biotherapeutics Inc. Data in Excel